Drugs / GSK2256294
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02262689 | Jan → Apr 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02006537 | Jan → May 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01762774 | Jan 2013 → May 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03486223 | May 2018 → Nov 2021 | diabetes mellitus, obesity disorder, prediabetes syndrome | Vanderbilt University Medical Center | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03318783 Comparator | May 2018 → Apr 2019 | acquired aneurysmal subarachnoid hemorrhage, brain ischemia, intracranial vasospasm | Oregon Health and Science University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2256294 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262689 ↗ |
| Known as | GSK-2256294A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3818875 ↗ |
| Action | Inhibit | “GSK2256294 is a potent and selective sEH inhibitor” PMID 26620151 ↗ Jan 20161“Epoxide hydratase inhibitor” CHEMBL3818875 ↗ |
| Modality | Small molecule | — CHEMBL3818875 ↗ |
| Route | Oral | “repeat oral doses of GSK2256294” NCT01762774 ↗ |
| Target | EPHX2 | “Epoxide hydratase inhibitor” CHEMBL3818875 ↗ |